New survival data for pembrolizumab plus axitinib in advanced kidney cancer

A paper published in The Lancet Oncology this month provides further follow-up data from the KEYNOTE-426 study, which shows superior efficacy of pembrolizumab plus axitinib over sunitinib in patients with untreated advanced renal cell carcinoma (RCC). Eight hundred and sixty one (861) patients were randomly assigned to receive pembrolizumab plus axitinib (432) or sunitinib (429). […]

read more

Safety and efficacy of tivozanib–nivolumab combination in patients with metastatic kidney cancer

In this phase 1b/2 study the researchers looked at a combination of tivozanib and nivolumab in 25 patients with metastatic renal cell carcinoma (RCC). Tivozanib is a targeted therapy called a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) that blocks the growth of blood vessels to the tumour, while nivolumab is an immune […]

read more

Cabozantinib plus atezolizumab as first-line treatment for advanced kidney cancer

Clinical trial, COSMIC-021, investigated a combination of cabozantinib and atezolizumab in untreated clear-cell renal cell carcinoma (RCC). There were two groups of patients; one on 60 mg of cabozantinib plus the standard dose of atezolizumab, and the other on 40 mg cabozantinib plus atezolizumab. The results were similar between the two doses and the time […]

read more

Cabozantinib plus atezolizumab for non-clear cell renal cell carcinoma

In this video interview with Dr Monty Pal from the City of Hope Hospital in California, treatment of non-clear cell renal cell carcinoma (RCC) with a combination of cabozantinib plus atezolizumab is discussed. Most research is focussed on clear cell RCC; however, non-clear cell RCC accounts for about 25% of all RCC diagnoses and usually […]

read more

Treatment selection for metastatic kidney cancer based on gene expression

The discovery of a reliable biomarker for metastatic renal cell carcinoma (RCC) to predict response to treatment has been difficult to identify. This study was presented at the European Society of Medical Oncology (ESMO) Virtual Congress in September this year. The interview started by describing the currently used scoring systems used to categorise patients into […]

read more

Avelumab plus axitinib combintion approved for untreated advanced kidney cancer in Scotland

The Sottish Medicine Consortium (SMC) have issued a final decision to recommend the avelumab plus axitinib combination for untreated advanced kidney cancer for patients in Scotland. We are delighted that as from today, kidney cancer patients in Scotland can get NHS funding for avelumab in combination with axitinib for the first-line treatment of patients with advanced or metastatic renal cell carcinoma […]

read more

Selection of advanced kidney cancer patients for nephrectomhy

In this study, 6,043 patients with metastatic renal cell carcinoma (RCC) had a nephrectomy while 489 did not and were follow-up. Age, stage, presence of metastases and tumour size were assessed. The study showed that there was no survival benefit for patients with stage T4 disease and metastases or older than 76 years of age […]

read more

Quality versus quantity of life with cabozantinib and sunitinib in advanced kidney cancer

Cabozantinib and sunitinib are both drugs that block the development of blood vessels to supply the tumour and are called vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). These drugs are used to treat patients with advanced kidney cancer. Clinical trials have shown that cabozantinib is better at extending survival than sunitinib, giving patients […]

read more

Most coronavirus-positive cancer patients are asymptomatic

Most studies have shown that many cancer patients are at high risk of developing severe forms of COVID-19. In a study of nearly 900 cancer patients with coronavirus in the UK, for instance, the death rate was estimated to be 33.6%, which is much higher than the general population. However, most of these patients were […]

read more

ESMO Virtual 2020: Impact of immunotherapy on quality of life

In this video interview, Dr Jeffrey Kirshner from the Haematology-Oncology Associates of Central New York Community Clinical Oncology Programme talks about a global review of data on quality of life in patients on immunotherapy that was presented at this year’s ESMO.  During the interview, Dr Kirshner mentions that quality of life is better with immunotherapy than […]

read more
Showing 1 to 10 of 215 results
  TOP